Nasdaq:US$15.59 (+0.15) | HKEX:HK$24.06 (-0.24) | AIM:£2.29 (-0.05)
搜索
新聞檔案

通過選擇所需的新聞類型，可以獲得最新的公告或演示文稿。

請使用 「新聞主題」進一步挑選公告類別。

所有公告的全文可以PDF文件的形式下載。 為方便起見，某些公告的部分或全部文字內容以網頁的方式呈現。 如存有任何不一致之處，請以PDF版本為準。

新聞類型
公告及新聞稿
演示文稿
新聞主題
其他業務
監管通知
腫瘤學 / 免疫學
集團
123456789
10
11121314151617
找到相關結果： 843
公告及新聞稿, 集團 | 2019-03-11

和黃中國醫藥科技公佈2018全年財務業績及臨床項目最新進展（只備英文版本）
London: Monday, March 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its audited financial results for the year ended December 31, 2018 and provides updates on key clinical programs. Video webcas
閱讀更多
Download Announcement (PDF)
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2019-02-12

沃利替尼/Imfinzi®聯合療法以治療晚期乳頭狀腎細胞癌為適應症的II臨床研究初步資料將於2019年ASCO泌尿生殖系統腫瘤研討會發表
香港：2019年2月12日，星期二：和黃中國醫藥科技有限公司（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦證交所：HCM）今日宣佈CALYPSO II期臨床研究中探索沃利替尼/Imfinzi®（durvalumab）聯
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 集團 | 2019-02-08

和黃中國醫藥科技計劃公佈2018年度全年財務業績（只備英文版本）
London: Friday, February 8, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March 11, 2019 at 7:00 am Greenwich Mean Time (GMT). An analyst pr
閱讀更多
Download Announcement (PDF)
公告及新聞稿, 新聞稿, 集團 | 2019-01-07

和黃中國醫藥科技將於第37屆摩根大通醫療健康年會上發表演講（只備英文版本）
Press Release London: Monday, January 7, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th Annual JP Morgan Healthcare Conference on Wednes
閱讀更多
Download Press Release (PDF)
公告及新聞稿, 監管通知 | 2018-12-31

Blocklisting Six Monthly Return
London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (
閱讀更多
公告及新聞稿, 監管通知 | 2018-12-31

Total Voting Rights
London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2018, the issued share capital of Chi-Med consisted of 66,657,745 ordinary shares of US$1.00 each
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-12-20

Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company
– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China –  – Chi-Med to assume all development costs of life cycle indications in
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-12-20

Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy
– Global SAVANNAH study of savolitinib / Tagrisso®combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showedMET-amplification among the most frequent mechanisms of acquired resistance to AstraZeneca’s Tagrisso® – – China
閱讀更多
公告及新聞稿, 監管通知 | 2018-12-14

TR-1: Form for notification of major holdings
公告及新聞稿, 監管通知 | 2018-11-30

Total Voting Rights
London: Friday, November 30, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2018, the issued share capital of Chi-Med consisted of 66,623,441 ordinary shares of US$1.00 each
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-11-29

和黃醫藥就評估索凡替尼和呋喹替尼 與PD-1檢查點抑製劑的聯合療法簽訂多項合作協議
2018年11月29日，星期四：和黃中國醫藥科技有限公司（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦證交所：HCM）簽訂了4項合作協議，對和黃醫藥的索凡替尼（surufatinib, 亦稱HMPL-012或sulfa
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-11-26

和黃醫藥宣布呋喹替尼膠囊（愛優特®）首次商業上市
2018年11月26日，星期一：和黃中國醫藥科技有限公司（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦證交所：HCM）今日宣布呋喹替尼膠囊（愛優特®）首次商業上市，並在中國開始產品銷
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 腫瘤學 / 免疫學 | 2018-11-16

和黃醫藥公佈呋喹替尼在中國以三線晚期非小細胞肺癌為適應症的 III期臨床試驗FALUCA研究結果
- 研究沒有達到總生存期的主要終點，但呋喹替尼組患者無進展生存期得到延長 -   2018年11月16日，週五：和黃中國醫藥科技有限公司（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦
閱讀更多
下載通告 (PDF)
公告及新聞稿, 監管通知 | 2018-10-31

Total Voting Rights
London: Wednesday, October 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at October 31, 2018, the issued share capital of Chi-Med consisted of 66,618,660 ordinary shares of US$1.00 eac
閱讀更多
公告及新聞稿, 監管通知 | 2018-10-22

Grant of Share Options under Share Option Scheme
London: Monday, October 22, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 19, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Mee
閱讀更多
公告及新聞稿, 腫瘤學 / 免疫學 | 2018-10-18

Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China
London: Thursday, October 18, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in combination with azacitidine, an approved nuc
閱讀更多
公告及新聞稿, 監管通知 | 2018-10-05

Appointment of HSBC Bank plc as Joint Corporate Broker in London
London: Friday, October 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has appointed HSBC Bank plc as its joint Corporate Broker in London with immediate effect. Panmure Gordon (UK) Limited will co
閱讀更多
公告及新聞稿, 腫瘤學 / 免疫學 | 2018-09-05

和黄医药宣布呋喹替尼胶囊在中国获批 用于治疗既往接受过其他治疗的结直肠癌患者
-呋喹替尼膠囊為轉移性結直腸癌患者提供了新的口服治療選擇，將在中國市場以商品名愛優特®進行銷售-   -已在JAMA發表的研究數據表明，和安慰劑相比愛優特®能夠使患者總生存期得到
閱讀更多
下載通告 (PDF)
公告及新聞稿, 監管通知 | 2018-08-31

Total Voting Rights
London: Friday, August 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 31, 2018, the issued share capital of Chi-Med consisted of 66,535,683 ordinary shares of US$1.00 each, wi
閱讀更多
公告及新聞稿, 監管通知 | 2018-08-07

Grant of Share Options under Share Option Scheme
London: Tuesday, August 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on August 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meetin
閱讀更多
公告及新聞稿, 集團 | 2018-07-27

Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs
London: Friday, July 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2018 and updates shareholders on key clinical programs. Fruquinti
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-07-23

和黃醫藥在美國啟動索凡替尼以胰腺神經內分泌瘤和膽管癌為適應症的Ib/II期概念驗證臨床試驗
2018年7月23日：和黃中國醫藥科技（簡稱「和黃醫藥」或「Chi-Med」）（納斯達克/倫敦證交所：HCM）今日宣佈在美國啟動索凡替尼以胰腺神經內分泌瘤（NET）和膽管癌（BTC）為適應症的Ib/II期
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2018-06-29

Total Voting Rights
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 29, 2018, the issued share capital of Chi-Med consisted of 66,532,683 ordinary shares of US$1.00 each, with e
閱讀更多
公告及新聞稿, 監管通知 | 2018-06-29

Blocklisting Six Monthly Return
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (a)
閱讀更多
公告及新聞稿, 新聞稿, 集團 | 2018-06-29

Chi-Med to Announce 2018 Half-Year Financial Results
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST). An analy
閱讀更多
公告及新聞稿, 監管通知 | 2018-06-07

Grant of Share Options under Share Option Scheme
London: Thursday, June 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on June 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting i
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-06-04

和黃醫藥在2018年ASCO年會上公佈呋喹替尼FRESCO研究更多研究數據
-繼2017年ASCO年會上就FRESCO研究達到全部研究終點，呋喹替尼安全性良好，較其他靶向療法脫靶毒性更低等數據進行口頭報告後，和黃醫藥在2018年ASCO年會上公佈了FRESCO研究進一步的研究數據-
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2018-05-31

Total Voting Rights
London: Thursday, May 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2018, the issued share capital of Chi-Med consisted of 66,515,756 ordinary shares of US$1.00 each, with e
閱讀更多
公告及新聞稿, 新聞稿, 集團 | 2018-05-11

Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference
Press Release   London: Friday, May 11, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that Christian Hogg, Chief Executive Officer, will present at the Bank of America Merrill Lynch 2018 Health Care Confe
閱讀更多
公告及新聞稿, 監管通知 | 2018-04-30

Total Voting Rights
London: Monday, April 30, 2018: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 30, 2018, the issued share capital of Chi-Med consisted of 66,484,620 ordinary sh
閱讀更多
公告及新聞稿, 監管通知 | 2018-04-27

Results of AGM Meeting
London: Friday, April 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2018 were duly pa
閱讀更多
公告及新聞稿, 監管通知 | 2018-04-23

Block Admission
London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,425,597 ordinary shares, par value of US$
閱讀更多
公告及新聞稿, 監管通知 | 2018-04-23

Grant of Share Options under Share Option Scheme
London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on April 20, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting
閱讀更多
公告及新聞稿, 監管通知 | 2018-03-29

Total Voting Rights
London: Thursday, March 29, 2018: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 29, 2018, the issued share capital of Chi-Med consisted of 66,476,279 ordinary
閱讀更多
公告及新聞稿, 監管通知 | 2018-03-28

Vesting of awards under the Long Term Incentive Plan
London: Wednesday, March 28, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that following the publication of the 2017 annual report of Chi-Med on March 26, 2018, the following awards granted under the Long Term In
閱讀更多
公告及新聞稿, 集團 | 2018-03-26

2017 Annual Report and Notice of Annual General Meeting
London: Monday, March 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2017 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.
閱讀更多
公告及新聞稿, 監管通知 | 2018-03-21

Director’s Share Dealing
London: Wednesday, March 21, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Graeme Jack, Independent Non-executive Director, purchased a total of 3,000 American Depositary Shar
閱讀更多
公告及新聞稿, 監管通知 | 2018-03-20

Grant of Share Options under Share Option Scheme
London: Tuesday, March 20, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 19, 2018, it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Meeting on April 24,
閱讀更多
公告及新聞稿, 監管通知 | 2018-03-19

Director's Share Dealing
London: Monday, March 19, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Dan Eldar, Non-executive Director, purchased a total of 2,768 American Depositary Shares of the Company (“ADSs”,
閱讀更多
公告及新聞稿, 集團 | 2018-03-12

Publication of Form 20-F for the Year Ended December 31, 2017
公告及新聞稿, 集團 | 2018-03-12

Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs
Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs Group: Year of major progress; results in line with guidance Group revenue up 12% to $
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-03-06

和黄医药在中国启动依吡替尼以胶质母细胞瘤为适应症的Ib/II期概念验证临床试验
2018年3月6日: 和黃醫藥今日宣佈在中國啟動依吡替尼Ib/II期概念驗證臨床試驗，目標受試者為表皮生長因子受體（EGFR）基因擴增的膠質母細胞瘤患者。膠質母細胞瘤是腦腫瘤的一種主要類型
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2018-02-13

和黃醫藥完成呋喹替尼以非小細胞肺癌為適應症的III期臨床試驗的患者入組工作，共招募527名患者
2018 年2 月13 日：和黃醫藥今日宣布呋喹替尼（HMPL-013）以非小細胞肺癌為適應症的III 期臨床試驗“FALUCA” 順利完成患者入組工作。呋喹替尼是一種高選擇性強效口服血管內皮生長因子受
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2018-02-05

Chi-Med to Announce 2017 Final Results
London: Monday, February 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2017 on Monday, March 12, 2018 at 7:00 am Greenwich Mean Time (GMT). An analy
閱讀更多
公告及新聞稿, 監管通知 | 2017-12-29

Total Voting Rights
London: Friday, December 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 29, 2017, the issued share capital of Chi-Med consisted of 66,447,037 ordin
閱讀更多
公告及新聞稿, 監管通知 | 2017-12-29

Blocklisting Six Monthly Return
London: Friday, December 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: H
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-12-15

和黃醫藥在美國啟動呋喹替尼臨床試驗
2017年12 月15日：和黃醫藥今日宣佈在美國啟動呋喹替尼I期橋接臨床試驗。呋喹替尼是一種高選擇性強效口服血管內皮生長因子受體（VEGFR）1,2及3的抑製劑。呋喹替尼在中國以結直腸癌、肺
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2017-11-01

TR-1: Notification of major interest in shares
公告及新聞稿, 監管通知 | 2017-11-01

TR-1: Notification of major interest in shares
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-10-31

和黃醫藥啟動呋喹替尼以二線胃癌為適應症的III期臨床研究FRUTIGA
2017年10月31日：和黃醫藥今日宣佈在中國啟動呋喹替尼聯合紫杉醇（泰素® ）以晚期胃癌或胃食管結合部（GEJ）腺癌為適應症的關鍵性III期臨床研究，這項研究被命名為FRUTIGA 。呋喹替尼是
閱讀更多
下載新聞稿 (PDF)
123456789
10
11121314151617